Fortress Biotech repays $15M in Oaktree debt

Q: How much did FBIO repay under the Oaktree Agreement?

Fortress Biotech repaid the remaining $15.0 million of principal, plus approximately $435,000 in accrued interest, a $150,000 prepayment fee and other closing costs.

Repayment satisfied the remaining indebtedness and released all liens and security interests securing the Oaktree facility.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Fortress Biotech, Inc. (FBIO) repaid in full the remaining $15.0 million in principal under its Oaktree Agreement on September 30, 2026. It also paid approximately $435,000 in accrued interest, a $150,000 prepayment fee and other closing costs.

Following repayment, all indebtedness under the agreement was satisfied and paid in full, all liens and other security interests securing it were released and terminated, and the agreement automatically terminated pursuant to its terms.

1 point · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

0 major · 0 points

How the balance works

Positive

Major pointOaktree facility’s $15.0 million remaining principal was repaid in full. 21% of market cap

Negative

None.

Insights

Analyzing...

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Outstanding principal repaid: $15.0 million Accrued interest: Approximately $435,000 Prepayment fee: $150,000 +1 more

4 metrics

Outstanding principal repaid $15.0 million Repaid on September 30, 2026

Accrued interest Approximately $435,000 Paid with the September 30, 2026 repayment

Prepayment fee $150,000 Paid with the September 30, 2026 repayment

Senior secured credit agreement $50.0 million Agreement entered into on July 25, 2024

Key Terms

senior secured credit agreement, prepayment fee, liens

3 terms

senior secured credit agreement financial

"entered into a $50.0 million senior secured credit agreement"

A senior secured credit agreement is a loan contract in which the borrower agrees to repay lenders first and backs the loan with specific assets as collateral, like a mortgage that gives a lender a claim on a house if payments stop. Investors care because this debt has priority over other obligations in a default, reducing lender risk and often constraining a company’s financial choices and cash flow, which can affect equity value and future financing.

prepayment fee financial

"a prepayment fee of $150,000"

liens financial

"all liens and other security interests in the Company’s property"

Liens are legal claims or rights that a creditor has over a person's property, such as a home or car, as a way to secure repayment of a debt. If the debt remains unpaid, the creditor may have the authority to take or sell the property to recover what is owed. For investors, liens can affect the value or sale of property and represent a potential risk or priority in getting paid during financial disputes.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did FBIO repay under the Oaktree Agreement?

Fortress Biotech repaid the remaining $15.0 million of principal, plus approximately $435,000 in accrued interest, a $150,000 prepayment fee and other closing costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/01/2026 - 04:31 PM Accepted by SEC EDGAR 10/01/2026 - 04:30 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 30, 2026

Fortress Biotech, Inc.

(Exact Name of Registrant as Specified in Charter)


Delaware (State or Other Jurisdiction of Incorporation)		001-35366 (Commission File Number)		20-5157386 (IRS Employer Identification No.)

1111 Kane Concourse, Suite 301

Bay Harbor Islands, FL 33154

(Address of Principal Executive Offices)

(781) 652-4500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act.

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

☐Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	FBIO	Nasdaq Capital Market
9.375% Series A Cumulative Redeemable Perpetual Preferred Stock	FBIOP	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

As previously disclosed, on July 25, 2024, Fortress Biotech, Inc. (the “Company”), as borrower, entered into a $50.0 million senior secured credit agreement (as amended on December 12, 2025 and February 22, 2026, the “Oaktree Agreement”) with Oaktree Fund Administration, LLC and the lenders from time-to-time party thereto. On September 30, 2026, the Company repaid in full the remaining $15.0 million in outstanding principal under the facility, together with approximately $435,000 in accrued interest, a prepayment fee of $150,000 and other closing costs. Upon such repayment, all indebtedness under the Oaktree Agreement was deemed satisfied and paid in full, all liens and other security interests in the Company’s property securing the indebtedness under the Oaktree Agreement were released and terminated and the Oaktree Agreement automatically terminated pursuant to its terms.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Fortress Biotech, Inc.
	(Registrant)

Date: October 1, 2026

	By:	/s/ David Jin
		David Jin
		Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents